Search for: "Sanofi S A"
Results 21 - 40
of 926
Sorted by Relevance
|
Sort by Date
5 Feb 2011, 8:18 pm
Reuters is reporting that Genzyme and Sanofi's respective boards will be meeting on Sunday. [read post]
27 Mar 2007, 5:07 am
A deal between Sanofi-Aventis, France’s largest drug company, and U.S. rival Bristol-Myers Squibb could still be in the offing. [read post]
10 Nov 2010, 1:46 pm
A state statute and a 2006 proxy vote by Genzyme add an interesting twist to a hostile takeover bid by Sanofi-Aventis and help to illustrate the difficulties of making a bid for a Massachusetts corporation. [read post]
23 Jul 2010, 1:38 pm
Sanofi-Aventis has made an informal takeover approach to Genzyme, a person briefed on the matter told DealBook on Friday, as the French drug maker seeks to bolster its biotechnology offerings. [read post]
7 Oct 2010, 2:38 pm
Genzyme said Thursday that its board had again rejected an $18.5 billion takeover offer from Sanofi-Aventis of France, saying the bid remains too low. [read post]
28 Aug 2012, 2:36 pm
Federal securities regulators charged eight people in Georgia with insider trading on Tuesday, saying they bought stock in a company ahead of a merger announcement after one of them learned about a pending acquisition by Sanofi-Aventis. [read post]
28 Aug 2012, 2:36 pm
Federal securities regulators on Tuesday charged eight people in Georgia with insider trading, saying they bought stock in a company ahead of a merger announcement after one of them learned about a pending acquisition by Sanofi-Aventis [read post]
28 Aug 2012, 2:36 pm
Federal securities regulators on Tuesday charged eight people in Georgia with insider trading, saying they bought stock in a company ahead of a merger announcement after one of them learned about a pending acquisition by Sanofi-Aventis [read post]
28 Aug 2012, 2:36 pm
Federal securities regulators on Tuesday charged eight people in Georgia with insider trading, saying they bought stock in a company ahead of a merger announcement after one of them learned about a pending acquisition by Sanofi-Aventis [read post]
15 Dec 2008, 9:51 pm
District Court for the Southern District of New York, following a 2007 bench trial, that Sanofi's U.S. [read post]
2 Jul 2010, 4:30 am
Sanofi-Aventis, the French drug giant, is reportedly preparing for a U.S acquisition that could be worth $20 billion or more, Bloomberg News reported. [read post]
4 Oct 2010, 10:42 am
Sanofi's chief executive told DealBook that Monday's tender offer for Genzyme shares makes sense, and that absent a firm valuation its $18.5 billion offer won't change. [read post]
8 Oct 2010, 6:49 am
The battle between Sanofi-Aventis and Genzyme is quickly becoming a war of words. [read post]
27 Mar 2023, 1:15 pm
Sanofi, a case that even Sanofi’s counsel agreed could effectively wipe out patents involving genus claims if the Court sides with Sanofi, or—as counsel for Sanofi and the Solicitor General’s Office suggested the Court could do—if it were to dismiss the case as improvidently granted. [read post]
27 Mar 2023, 1:15 pm
Sanofi, a case that even Sanofi’s counsel agreed could effectively wipe out patents involving genus claims if the Court sides with Sanofi, or—as counsel for Sanofi and the Solicitor General’s Office suggested the Court could do—if it were to dismiss the case as improvidently granted. [read post]
30 Jun 2021, 5:27 am
The carcinogen that was found in Zantac’s chemical makeup is nitrosodimethylamine (NDMA). [read post]
30 Jun 2021, 5:27 am
The carcinogen that was found in Zantac’s chemical makeup is nitrosodimethylamine (NDMA). [read post]
30 Jun 2021, 5:27 am
The carcinogen that was found in Zantac’s chemical makeup is nitrosodimethylamine (NDMA). [read post]
20 Oct 2010, 7:05 am
In a five-week bench trial in 2007, a judge found that Sanofi's patent on Plavix, the world's second biggest-selling drug, was valid and enforceable, and that Apotex violated the patent by making and distributing a generic form of the drug. [read post]
28 Oct 2010, 4:38 am
The chief executive of Sanofi-Aventis reiterated his belief that French company's $18.5 billion hostile bid for Genzyme represented good value for the U.S. biotechnology firm, saying: "Nothing in what Genzyme has said in recent weeks would cause us to change our offer. [read post]
